Literature DB >> 11956890

Ask the expert. Does antibody induction therapy with daclizumab or basiliximab increase the risk of recurrence of post-transplant focal segmental glomerulosclerosis?

Marie-France Gagnadoux1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2002        PMID： 11956890     DOI： 10.1007/s00467-002-0828-z

Source DB:  PubMed          Journal:  Pediatr Nephrol        ISSN： 0931-041X            Impact factor:   3.714


× No keyword cloud information.
  2 in total

1.  Role of transplant induction therapy on recurrence rate of focal segmental glomerulosclerosis.

Authors:  R Raafat; L B Travis; A Kalia; S Diven
Journal:  Pediatr Nephrol       Date:  2000-03       Impact factor: 3.714

2.  Anti-interleukin 8 antibody abolishes effects of lipoid nephrosis cytokine.

Authors:  E H Garin; P Laflam; L Chandler
Journal:  Pediatr Nephrol       Date:  1998-06       Impact factor: 3.714
  2 in total
  3 in total

1.  Recurrent focal glomerulosclerosis in pediatric renal allografts: the Miami experience.

Authors:  Hans Hubsch; Brenda Montané; Carolyn Abitbol; Jayanthi Chandar; Sherry Shariatmadar; Gaetano Ciancio; George Burke; Joshua Miller; José Strauss; Gastón Zilleruelo
Journal:  Pediatr Nephrol       Date:  2004-12-17       Impact factor: 3.714

2.  Long-term outcome of focal segmental glomerulosclerosis after pediatric renal transplantation.

Authors:  Gabriel M Cara Fuentes; Carmen Garcia Meseguer; Antonia Peña Carrion; Marta Melgosa Hijosa; Araceli Garcia-Pose; Angel Alonso Melgar; Mercedes Navarro Torres
Journal:  Pediatr Nephrol       Date:  2009-12-03       Impact factor: 3.714

Review 3.  Recurrence of nephrotic syndrome/focal segmental glomerulosclerosis following renal transplantation in children.

Authors:  Richard N Fine
Journal:  Pediatr Nephrol       Date:  2006-12-21       Impact factor: 3.714
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.